Abstract
Background: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) currently present a therapeutic challenge. A pharmaceutical cannabidiol (CBD) specialty (Epidyolex®) has been approved by the FDA and EMA for the treatment of seizures in these syndromes. However, in Italy, the use of galenic formulations versus the pharmaceutical CBD has not been clearly regulated.
Aim: To share and disseminate expert’ opinions on how to use and administer pharmaceutical CBD in patients with DS and LGS as well as identifying a possible strategy for the switch from galenic to pharmaceutical specialty.
Methods: A nominal group technique (NGT) was used, involving eight Italian adult and pediatric neurologists. Two questionnaires were consecutively administered and the Clinician’ responses were discussed in a final meeting in order to draw the own conclusions.
Results: The use of a pharmaceutical CBD is considered preferable to galenic formulations, in terms of reproducibility, safety, and control of the delivered dose.
Conclusion: The use of a pharmaceutical CBD in DS and LGS patients is useful for both seizure treatment and quality of life (QoL) improvement. However, further studies are needed to confirm the improvement in QoL and the best strategy for switching from a galenic formulation to pharmaceutical CBD.
Keywords: Epilepsy. LennoxGastaut syndrome, cannabidiol, developmental and epileptic encephalopathies. dravet syndrome
Similar articles
-
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.CNS Drugs. 2021 Mar;35(3):265-281. doi: 10.1007/s40263-021-00807-y. Epub 2021 Mar 22.PMID: 33754312 Free PMC article.
-
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.Epilepsy Res. 2019 Aug;154:13-20. doi: 10.1016/j.eplepsyres.2019.03.015. Epub 2019 Mar 25.PMID: 31022635 Clinical Trial.
-
Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2020 Oct;38(10):1043-1053. doi: 10.1007/s40273-020-00932-4.PMID: 32514751 Review.
-
Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea.J Korean Med Sci. 2020 Dec 28;35(50):e427. doi: 10.3346/jkms.2020.35.e427.PMID: 33372424 Free PMC article.
-
Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts’ recommendations for its use in clinical practice in Spain.Rev Neurol. 2021 Sep 10;73(S01):S1-S8. doi: 10.33588/rn.73S01.2021250.PMID: 34486101 Review. English, Spanish.
LinkOut – more resources
-
Full Text Sources
-
Research Materials